Opening Day: Inhibikase Falls Below IPO Price In First Trading Day

Laboratory Test Tubes

Image Source: Unsplash

Latest IPOs

Inhibikase Therapeutics (IKT) opened on December 23 at $10.67. The company had priced 1.36 million shares at $10.00. The deal size was increased to 1.8 million shares from 1.36 million shares, and the range was $10.00-$12.00. ThinkEquity acted as sole book running manager for the offering.

Inhibikase uses small-molecule oral protein kinase inhibitors to treat Parkinson’s disease and the gastrointestinal issues that arise in early stages of the disease. Inhibikase Therapeutics finished the week at $9.80.

SPAC IPOs

  • CF Acquisition Corp. IV (CFIV) opened on December 23 at $10.25. The blank check company had priced its upsized initial public offering of 45 million units at $10.00 per unit. CF Acquisition Corp. IV intends to focus on industries "where its management team and founders have experience, including the financial services, healthcare, real estate services, technology, and software industries."
  • 7GC & Co. Holdings (VIIA) opened on December 23 at $10.34. The blank check company had priced its upsized initial public offering of 20 million units at $10.00 per unit. While 7GC & Co. Holdings may pursue an initial business combination target in any industry or sector, it intends to concentrate its efforts in identifying businesses in the technology industry.
  • Viveon Health Acquisition (VHAQ) opened on Decmber 23 at $10.40. The blank check company had priced its initial public offering of 17.5 million units at $10.00 per unit.
  • Ackrell SPAC Partners I Co. (ACKIT) opened on December 21 at $10.09. The blank check company had priced its upsized initial public offering of 12 million units at $10.00 per unit. Ackrell intends to concentrate its efforts on identifying businesses in the "branded fast-moving consumer goods industry."

Upcoming IPOs 

Among the upcoming IPOs are Coinbase (COIN), Caliber Home Loans (HOMS), and Pharming Group (PHAR).

1 2
View single page >> |

"Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, analyst commentary, and upcoming IPOs.

Disclaimer: TheFly's news ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.